We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00212290
First Posted: September 21, 2005
Last Update Posted: February 15, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Purpose
The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.

Condition Intervention Phase
Insulin Resistance Type 2 Diabetes Mellitus Drug: pioglitazone Drug: nateglinide Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • Verbal memory (main study)
  • Selective attention (main study)
  • Plasma beta-amyloid levels (main study)
  • Cerebral glucose metabolism (sub-study)
  • Inflammatory markers in spinal fluid (sub-study)
  • Beta-amyloid in spinal fluid (sub-study)

Secondary Outcome Measures:
  • Psychomotor speed
  • Verbal fluency
  • Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers

Estimated Enrollment: 140
Study Start Date: November 2002
Study Completion Date: December 2006
Detailed Description:
Insulin resistant conditions such as impaired glucose tolerance, type 2 diabetes mellitus, and hyperinsulinemia have been associated with an increased risk for memory decline and for Alzheimer's disease. The main study will determine whether treatment with pioglitazone or nateglinide will improve verbal memory and selective attention for older adults with impaired glucose tolerance or mild type 2 diabetes. The main study will also characterize changes in blood concentrations of insulin, inflammatory markers, and the beta-amyloid peptides that are related to Alzheimer's disease. In one sub-study, participants will undergo brain positron emission tomography (PET) imaging before and after 16 weeks of treatment with pioglitazone, nateglinide, or placebo. The purpose of this sub-study is to determine the effects of treatment on brain glucose utilization. In a second sub-study, participants will undergo a lumbar puncture procedure before and after treatment. The purpose of this sub-study is to determine the effects of treatment on spinal fluid concentrations of insulin, inflammatory markers, and beta-amyloid peptides. Together these main and sub-studies should characterize the effects of insulin resistance on cognition and suggest a mechanism by which insulin resistant conditions increase risk for memory decline and for Alzheimer's disease.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Impaired glucose tolerance OR mild type 2 diabetes mellitus OR normal blood sugar regulation
  • Stable weight and activity level

Exclusion Criteria:

  • Medications for diabetes
  • Dementia
  • Medications with known effects on memory
  • Serious neurologic disease or head trauma
  • Serious systemic illness (e.g., renal failure or uncontrolled hypertension)
  • Serious psychiatric illness (e.g., schizophrenia or bipolar disorder)
  • Allergy to pioglitazone or nateglinide
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00212290


Locations
United States, Washington
VA Puget Sound Health Care System (Seattle Campus)
Seattle, Washington, United States, 98108
VA Puget Sound Health Care System (American Lake Campus)
Tacoma, Washington, United States, 98493
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Suzanne Craft, PhD VA Puget Sound Health Care System, University of Washington
  More Information

ClinicalTrials.gov Identifier: NCT00212290     History of Changes
Other Study ID Numbers: DK61606 (completed)
First Submitted: September 20, 2005
First Posted: September 21, 2005
Last Update Posted: February 15, 2010
Last Verified: February 2010

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
impaired glucose tolerance

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperinsulinism
Pioglitazone
Nateglinide
Hypoglycemic Agents
Physiological Effects of Drugs